☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
jazz pharmaceuticals
Jazz Pharmaceuticals to Acquire Chimerix for ~$935M
March 6, 2025
Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary...
November 21, 2024
Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program
February 8, 2024
Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in...
November 8, 2023
Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value
March 29, 2023
Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England
February 1, 2023
PharmaShots Weekly Snapshots (November 06–10, 2023)
November 10, 2023
Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in...
November 8, 2023
Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value
March 29, 2023
Top 20 Life Sciences Deals of 2022 by Total Deal Value
February 8, 2023
PharmaShots Weekly Snapshots (January 30 - February 03, 2023)
February 3, 2023
Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England
February 1, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.